Stocktoria
Spero Therapeutics, Inc. SPRO
Spero Therapeutics, Inc. (SPRO) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $66.8M at a 12.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.848 |
| Retained earnings / assets | -6.545 |
| EBIT / assets | 0.092 |
| Equity / liabilities | 5.963 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics, Inc. | 4/9 | -8.9 | 15.3 | +39.2% |
| AYTU | AYTU BIOPHARMA, INC | 4/9 | -8.14 | — | +1.8% |
| KURA | Kura Oncology, Inc. | 2/9 | -2.37 | — | +25.2% |
| ENTA | ENANTA PHARMACEUTICALS INC | 4/9 | -2.79 | — | -3.4% |
| RMTI | ROCKWELL MEDICAL, INC. | 2/9 | -18.33 | — | -31.8% |
| FBIO | Fortress Biotech, Inc. | 4/9 | -12.29 | 13.5 | +9.7% |
| NUVB | Nuvation Bio Inc. | 3/9 | -2.01 | — | — |
About Spero Therapeutics, Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
FAQ
Is SPRO financially healthy?
Spero Therapeutics, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SPRO pay a dividend?
No, Spero Therapeutics, Inc. does not currently pay a dividend.
How profitable is SPRO?
In FY2025, Spero Therapeutics, Inc. had a net margin of 12.8% and a return on equity of 14.5%.
What is SPRO's P/E ratio?
Spero Therapeutics, Inc.'s trailing price-to-earnings (P/E) ratio is about 15.3×, based on its latest annual earnings.
What is the analyst price target for SPRO?
The average Wall-Street price target for Spero Therapeutics, Inc. is $4.00, about 236.1% above the recent price, from 1 analysts (consensus: hold).
Is SPRO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Spero Therapeutics, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone, a P/E of about 15.3×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.